Data gathered: December 21
AI Stock Analysis - Axsome Therapeutics (AXSM)
Analysis generated February 7, 2024. Powered by Chat GPT.
Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies to manage central nervous system (CNS) disorders. They aim to improve the lives of patients living with pain, neuropsychiatric disorders, and other chronic conditions. Their product pipeline is diverse with treatments being developed for major depressive disorder, migraine, and narcolepsy among others, highlighting their commitment to innovation in the healthcare sector.
Stock Alerts - Axsome Therapeutics (AXSM)
 |
Axsome Therapeutics | December 17 Employee Rating is down by 2.6% over the last month. |
|
Axsome Therapeutics | November 21 Price is up by 5% in the last 24h. |
|
Axsome Therapeutics | November 13 Price is up by 5.1% in the last 24h. |
|
Axsome Therapeutics | November 12 Price is up by 9.7% in the last 24h. |
Alternative Data for Axsome Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 51 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 19,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 21 | Sign up | Sign up | Sign up |
| Patents | 243 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 19 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 11,096 | Sign up | Sign up | Sign up |
| Twitter Followers | 431 | Sign up | Sign up | Sign up |
| Twitter Mentions | 14 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 89 | Sign up | Sign up | Sign up |
| Linkedin Employees | 605 | Sign up | Sign up | Sign up |
About Axsome Therapeutics
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
| Price | $90.73 |
| Target Price | Sign up |
| Volume | 825,360 |
| Market Cap | $4.35B |
| Year Range | $65.72 - $100.49 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Geode Capital Management LLC Grows Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)December 21 - ETF Daily News |
|
Barclays PLC Buys 45,509 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)December 21 - ETF Daily News |
|
State Street Corp Cuts Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)December 17 - ETF Daily News |
|
Axsome Therapeutics (NASDAQ:AXSM) Earns “Overweight” Rating from Cantor FitzgeraldDecember 14 - ETF Daily News |
|
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 8,479 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)December 13 - ETF Daily News |
 |
Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report?December 12 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 105M | 106M | -1.2M | -65M | -57M | 0.000 |
| Q2 '24 | 87M | 113M | -26M | -79M | -72M | -1.670 |
| Q1 '24 | 69M | 107M | -38M | -68M | -61M | -1.440 |
| Q4 '23 | 66M | 96M | -30M | -99M | -92M | -2.080 |
| Q3 '23 | 53M | 91M | -39M | -62M | -56M | -1.320 |
Insider Transactions View All
| Saad Mark E filed to sell 10,002 shares at $91.3. September 11 '24 |
| Jacobson Mark L. filed to sell 5,783 shares at $84.3. August 9 '24 |
| Coleman Mark filed to sell 14,600 shares at $75.1. May 29 '24 |
| Jacobson Mark L. filed to sell 5,783 shares at $74.3. May 29 '24 |
| Coleman Mark filed to sell 19,848 shares at $75.2. May 29 '24 |
Similar companies
Read more about Axsome Therapeutics (AXSM) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Axsome Therapeutics?
The Market Cap of Axsome Therapeutics is $4.35B.
What is the current stock price of Axsome Therapeutics?
Currently, the price of one share of Axsome Therapeutics stock is $90.73.
How can I analyze the AXSM stock price chart for investment decisions?
The AXSM stock price chart above provides a comprehensive visual representation of Axsome Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Axsome Therapeutics shares. Our platform offers an up-to-date AXSM stock price chart, along with technical data analysis and alternative data insights.
Does AXSM offer dividends to its shareholders?
As of our latest update, Axsome Therapeutics (AXSM) does not offer dividends to its shareholders. Investors interested in Axsome Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Axsome Therapeutics?
Some of the similar stocks of Axsome Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.